This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gunningham, S. P. Articles by Fox, S. B. Search for Related Content PubMed PubMed Citation Articles by Gunningham, S. P. Articles by Fox, S. B.

Vascular Endothelial Growth Factor-B and Vascular Endothelial Growth Factor-C Expression in Renal Cell Carcinomas

Regulation by the von Hippel-Lindau Gene and Hypoxia

Departments of Anatomical Pathology [S. P. G., M. J. C., S. B. F.] and Oncology [P. A. E. S., B. A. R.], Canterbury Health, Christchurch Hospital, Christchurch, New Zealand, and Department of Molecular Oncology, Imperial Cancer Research Fund, University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DS, United Kingdom [C. H., K. T., A. L. H.]

Angiogenesis is essential for tumor growth and metastasis. It is regulated by numerous angiogenic factors, one of the most important being vascular endothelial growth factor (VEGF). Recently VEGF-B and VEGF-C, two new VEGF family members, have been identified that bind to the tyrosine kinase receptors flt-1 (VEGFR1), KDR (VEGFR2), and flt-4 (VEGFR3). Although the importance of VEGF-A has been shown in renal carcinomas, the contribution of these new ligands in kidney tumors is not clear. We have, therefore, measured the mRNA level of VEGF-B and VEGF-C together with their receptors by RNase protection assay (RPA) in 26 normal kidney samples and 45 renal cell cancers. We observed a significant up-regulation of VEGF-B (P = 0.002) but not VEGF-C (P = 0.3) in neoplastic kidney compared with normal tissues. In addition, although VEGF receptors were higher in tumors than normal kidney, there was a significant up-regulation of only flt-1 (P = 0.003) but not KDR (P = 0.12) or flt-4 (P = 0.09). There was also a significant correlation between VEGF-C and both of its receptors flt-4 (P = 0.006) and KDR (P = 0.03) but no association between VEGF-B and its receptor flt-1 (P = 0.23). A significant increase was observed in flt-1 (P < 0.001), KDR (P = 0.02), and flt-4 (P = 0.01) but not VEGF-B (P = 0.82) or VEGF-C (P = 0.52) expression in clear cell compared with chromophil (papillary) carcinomas. No significant association was demonstrated between VEGF-B, VEGF-C, flt-1, KDR, and flt-4 with patient sex, patient age, or tumor size (P > 0.05). The effect of von Hippel-Lindau (VHL) gene and hypoxia on VEGF-B and VEGF-C expression in the renal carcinoma cell line 786–0 transfected with wild-type and mutant VHL was determined by growing cells under 21% O_2- and 0.1% O₂. In wild-type VHL cells, whereas VEGF-A was significantly up-regulated under hypoxic compared with normoxic conditions (P < 0.001), expression of VEGF-C was reduced (P < 0.002). Nevertheless, the repression of VEGF-C was lost in mutant VHL cell lines under hypoxia. In contrast VEGF-B was not regulated by VHL despite clear up-regulation in vivo. These findings strongly support an enhanced role for this pathway in clear cell carcinomas by regulating angiogenesis and/or lymphangiogenesis. The study shows that clear cell tumors are able to up-regulate angiogenic growth factor receptors more efficiently than chromophil (papillary), that clear cell tumors can use pathways independent of VHL to regulate angiogenesis, and that this combined regulation may account for their more aggressive phenotype, which suggests that targeting VEGFR1 (flt-1) may be particularly effective in these tumor types.

This article has been cited by other articles:

				T. B. Dorff, A. Goldkorn, and D. I. Quinn Review: Targeted therapy in renal cancer Therapeutic Advances in Medical Oncology, November 1, 2009; 1(3): 183 - 205. [Abstract] [PDF]

				D. D. Hu-Lowe, H. Y. Zou, M. L. Grazzini, M. E. Hallin, G. R. Wickman, K. Amundson, J. H. Chen, D. A. Rewolinski, S. Yamazaki, E. Y. Wu, et al. Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 Clin. Cancer Res., November 15, 2008; 14(22): 7272 - 7283. [Abstract] [Full Text] [PDF]

				K. Poesen, D. Lambrechts, P. Van Damme, J. Dhondt, F. Bender, N. Frank, E. Bogaert, B. Claes, L. Heylen, A. Verheyen, et al. Novel Role for Vascular Endothelial Growth Factor (VEGF) Receptor-1 and Its Ligand VEGF-B in Motor Neuron Degeneration J. Neurosci., October 15, 2008; 28(42): 10451 - 10459. [Abstract] [Full Text] [PDF]

				S. M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J. M. Llovet, and M. Lynch Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling Mol. Cancer Ther., October 1, 2008; 7(10): 3129 - 3140. [Abstract] [Full Text] [PDF]

				R. R. Foster, S. C. Satchell, J. Seckley, M. S. Emmett, K. Joory, C. Y. Xing, M. A. Saleem, P. W. Mathieson, D. O. Bates, and S. J. Harper VEGF-C promotes survival in podocytes Am J Physiol Renal Physiol, July 1, 2006; 291(1): F196 - F207. [Abstract] [Full Text] [PDF]

				T. Jacob, E. Ascher, A. Hingorani, and S. Kallakuri The Effect of Von Hippel-Lindau Gene Transfer on Human Vascular Smooth Muscle Cell Proliferation and Apoptosis Vascular and Endovascular Surgery, January 1, 2005; 39(1): 25 - 32. [Abstract] [PDF]

				M. Hernberg, P. Virkkunen, P. Bono, H. Ahtinen, H. Maenpaa, and H. Joensuu Interferon Alfa-2b Three Times Daily and Thalidomide in the Treatment of Metastatic Renal Cell Carcinoma J. Clin. Oncol., October 15, 2003; 21(20): 3770 - 3776. [Abstract] [Full Text] [PDF]

				S. Turcotte, R. R. Desrosiers, and R. Beliveau HIF-1{alpha} mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma J. Cell Sci., June 1, 2003; 116(11): 2247 - 2260. [Abstract] [Full Text] [PDF]